CD44 and breast carcinoma: Two gene-expression profiling studies, comparing CD24−/low/CD44+ cell populations with other populations in primary breast cancer cells or in normal tissue, presented the CD24−/low/CD44+ cell population-derived different signatures that seemed to predict poorer prognosis (Liu et al, 2007; Shipitsin et al, 2007).